DE3788984D1 - Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom. - Google Patents

Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.

Info

Publication number
DE3788984D1
DE3788984D1 DE87107049T DE3788984T DE3788984D1 DE 3788984 D1 DE3788984 D1 DE 3788984D1 DE 87107049 T DE87107049 T DE 87107049T DE 3788984 T DE3788984 T DE 3788984T DE 3788984 D1 DE3788984 D1 DE 3788984D1
Authority
DE
Germany
Prior art keywords
prostaglandin
glaucoma
treatment
active substances
eye hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE87107049T
Other languages
English (en)
Other versions
DE3788984T2 (de
Inventor
Yasumasa Goh
Osamu Royal Court Shi Hayaishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Shionogi and Co Ltd
Original Assignee
Research Development Corp of Japan
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Corp of Japan, Shionogi and Co Ltd filed Critical Research Development Corp of Japan
Application granted granted Critical
Publication of DE3788984D1 publication Critical patent/DE3788984D1/de
Publication of DE3788984T2 publication Critical patent/DE3788984T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3788984T 1986-05-16 1987-05-15 Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom. Expired - Fee Related DE3788984T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11314086 1986-05-16

Publications (2)

Publication Number Publication Date
DE3788984D1 true DE3788984D1 (de) 1994-03-17
DE3788984T2 DE3788984T2 (de) 1994-08-18

Family

ID=14604577

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3788984T Expired - Fee Related DE3788984T2 (de) 1986-05-16 1987-05-15 Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.

Country Status (4)

Country Link
US (1) US4824857A (de)
EP (1) EP0253094B1 (de)
JP (1) JPH0623106B2 (de)
DE (1) DE3788984T2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE03014533T1 (de) * 1988-09-06 2004-07-15 Pharmacia Ab Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
US5011856A (en) * 1990-03-12 1991-04-30 Allergan, Inc. Use of prostaglandin F3 α as an ocular hypotensive agent
EP0458590B1 (de) * 1990-05-22 1996-01-10 R-Tech Ueno Ltd. Behandlung von intraokularem Druck mit einer synergischen Kombination
DE69106777T2 (de) * 1990-05-22 1995-05-18 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
DK0458587T3 (da) * 1990-05-22 1993-08-23 R Tech Ueno Ltd Behandling af okulær hypertension med en synergistisk kombination til ophthalmisk anvendelse
US5238961A (en) * 1990-06-14 1993-08-24 Allergan, Inc. Pgf 1-alcohols and their use as ocular hypotensives
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
BR9107162A (pt) * 1990-12-10 1994-06-21 Allergan Inc Derivados da homo-prostaglandina como hipotensivos oculares
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
JP2769294B2 (ja) * 1993-12-15 1998-06-25 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物及びそのためのプロスタグランジン化合物
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1998033497A1 (en) 1997-02-04 1998-08-06 Johnstone Murray A Method of enhancing hair growth
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
EP1251862B1 (de) 2000-01-18 2008-10-01 Merck & Co., Inc. Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
WO2003077845A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
WO2003103664A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
EP1515721A4 (de) * 2002-06-14 2006-07-26 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1515974A4 (de) * 2002-06-17 2007-02-28 Merck & Co Inc Neue maxi-k-kanalblocker, anwendungsverfahren und verfahren zu dessen herstellung
US20050239787A1 (en) * 2002-06-17 2005-10-27 Goetz Michael A Novel maxi-k channel blockers, methods of use and process for making the same
EP1515722A4 (de) * 2002-06-17 2006-06-21 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US7109223B2 (en) * 2002-08-28 2006-09-19 Merck & Co. Inc. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
EP1558602A2 (de) * 2002-10-25 2005-08-03 Merck Frosst Canada Inc. 2-pyrrolidone als ep4-rezeptor agonisten
US7414067B2 (en) * 2003-03-27 2008-08-19 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7642370B2 (en) 2006-08-07 2010-01-05 Daiichi Fine Chemical Co., Ltd. Method for preparing prostaglandin derivative
EP2057128A2 (de) * 2006-09-01 2009-05-13 Allergan, Inc. Therapeutische substituierte hydantoine und entsprechende verbindungen
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
EP0242580B1 (de) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Verwendung von A-, B- und C-Prostaglandinen und deren Derivaten zur Behandlung von Augen-Hypertension und Glaukom

Also Published As

Publication number Publication date
DE3788984T2 (de) 1994-08-18
JPH0623106B2 (ja) 1994-03-30
US4824857A (en) 1989-04-25
EP0253094A3 (en) 1990-08-22
JPS63107927A (ja) 1988-05-12
EP0253094B1 (de) 1994-02-02
EP0253094A2 (de) 1988-01-20

Similar Documents

Publication Publication Date Title
DE3788984D1 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE3785602D1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
ATE131068T1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE68920775D1 (de) Behandlung von faserigen Materialien.
DE68929563D1 (de) Prostaglandin-Derivate zur Behandlung von Glaukom und ocularer Hypertension
DE69019774D1 (de) Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
ATE33098T1 (de) Celiprolol zur behandlung von glaukom.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3777861D1 (de) Behandlung von gasen.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
DE3679781D1 (de) Verwendung von zusammensetzungen fuer die behandlung und die prophylaxe von epithelialer zerstoerung.
DE69004301D1 (de) Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68908404D1 (de) Lang haltende zusammensetzung von propafenon und chinidin zur behandlung des zustandes des herzens.
DE3668338D1 (de) Kontinuierliche behandlung von spannungslosem gewebe.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE74537T1 (de) Behandlung von gebrauchten antimonhalidkatalysatoren.
ATE136463T1 (de) Verwendung von 1,2,3,4-tetrahydroacridinen zur behandlung von aids, sowie verbindungen
DE68929177D1 (de) Verwendung von Dihydropyridinen zur Vorbeugung und Behandlung cerebraler Durchblutungsstörungen
ATE88636T1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augenhypertension und glaukom.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee